BR112022025991A2 - Composições de lnp compreendendo terapêutica de mrna com meia-vida prolongada - Google Patents
Composições de lnp compreendendo terapêutica de mrna com meia-vida prolongadaInfo
- Publication number
- BR112022025991A2 BR112022025991A2 BR112022025991A BR112022025991A BR112022025991A2 BR 112022025991 A2 BR112022025991 A2 BR 112022025991A2 BR 112022025991 A BR112022025991 A BR 112022025991A BR 112022025991 A BR112022025991 A BR 112022025991A BR 112022025991 A2 BR112022025991 A2 BR 112022025991A2
- Authority
- BR
- Brazil
- Prior art keywords
- life
- lnp compositions
- payload
- extended half
- mrna therapy
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 108020004999 messenger RNA Proteins 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 4
- 102000040430 polynucleotide Human genes 0.000 abstract 4
- 239000002157 polynucleotide Substances 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063042822P | 2020-06-23 | 2020-06-23 | |
| US202163165094P | 2021-03-23 | 2021-03-23 | |
| US202163165469P | 2021-03-24 | 2021-03-24 | |
| PCT/US2021/038780 WO2021262909A2 (en) | 2020-06-23 | 2021-06-23 | Lnp compositions comprising mrna therapeutics with extended half-life |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022025991A2 true BR112022025991A2 (pt) | 2023-03-14 |
Family
ID=77155849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022025991A BR112022025991A2 (pt) | 2020-06-23 | 2021-06-23 | Composições de lnp compreendendo terapêutica de mrna com meia-vida prolongada |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230242908A1 (https=) |
| EP (1) | EP4168556A2 (https=) |
| JP (1) | JP2023531511A (https=) |
| KR (1) | KR20230042005A (https=) |
| CN (1) | CN116194151A (https=) |
| AU (1) | AU2021297248A1 (https=) |
| BR (1) | BR112022025991A2 (https=) |
| CA (1) | CA3187261A1 (https=) |
| IL (1) | IL299196A (https=) |
| MX (1) | MX2022016550A (https=) |
| WO (1) | WO2021262909A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250313830A1 (en) * | 2022-03-25 | 2025-10-09 | Modernatx, Inc. | Messenger ribonucleic acids with extended half-life |
| US20250221931A1 (en) * | 2022-03-25 | 2025-07-10 | Modernatx, Inc. | Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia |
| WO2023196399A1 (en) * | 2022-04-06 | 2023-10-12 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria |
| WO2023215498A2 (en) * | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
| KR20250047488A (ko) * | 2023-09-27 | 2025-04-04 | 한미약품 주식회사 | 변형된 폴리아데닐 서열을 포함하는 핵산 분자 |
| KR20250047490A (ko) * | 2023-09-27 | 2025-04-04 | 한미약품 주식회사 | 변형된 폴리아데닐 서열 및 ox40l 단백질 코딩서열을 포함하는 핵산 분자 |
| KR20250047489A (ko) * | 2023-09-27 | 2025-04-04 | 한미약품 주식회사 | 변형된 폴리아데닐 서열 및 p53 단백질 코딩서열을 포함하는 핵산 분자 |
| CN117603029B (zh) * | 2023-11-21 | 2025-12-19 | 江苏禾本生化有限公司 | 一种戊菌唑关键中间体的合成方法 |
| WO2025255199A1 (en) * | 2024-06-05 | 2025-12-11 | Modernatx, Inc. | Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof |
| WO2026085234A1 (en) * | 2024-10-18 | 2026-04-23 | Modernatx, Inc. | 3' untranslated region sequences for extending messenger ribonucleic acids half-life |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8613481D0 (en) | 1986-06-04 | 1986-07-09 | Diatech Ltd | Translation of mrna |
| GB2284210B (en) | 1993-11-26 | 1997-11-12 | British Tech Group | Translational enhancer DNA from a kinesin gene |
| US5824497A (en) | 1995-02-10 | 1998-10-20 | Mcmaster University | High efficiency translation of mRNA molecules |
| EP2447370B1 (en) | 2001-09-28 | 2018-07-18 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MicroRNA molecules |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| CA2715078C (en) | 2007-09-26 | 2019-07-23 | Intrexon Corporation | Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression |
| EP2288336B8 (en) | 2008-04-25 | 2017-03-22 | Northwestern University | Nanostructures suitable for sequestering cholesterol |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| KR101766408B1 (ko) | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| CA2824526C (en) | 2011-01-11 | 2020-07-07 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
| AU2013374345A1 (en) | 2013-01-17 | 2015-08-06 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
| US20160022840A1 (en) | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| US10821175B2 (en) | 2014-02-25 | 2020-11-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| WO2017066797A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Trinucleotide mrna cap analogs |
| JP7194594B2 (ja) | 2016-05-18 | 2022-12-22 | モデルナティエックス インコーポレイテッド | 免疫調節ポリペプチドをコードするｍＲＮＡの組み合わせ及びその使用 |
| MX2021003015A (es) * | 2018-09-13 | 2021-07-15 | Modernatx Inc | Polinucleotidos que codifican glucosa-6-fosfatasa para el tratamiento de la glucogenosis. |
| JP2022500444A (ja) * | 2018-09-14 | 2022-01-04 | モダーナティエックス・インコーポレイテッドModernaTX, Inc. | クリグラー−ナジャー症候群の治療のためのウリジン二リン酸グリコシルトランスフェラーゼ１ファミリー、ポリペプチドａ１をコードするポリヌクレオチド |
| AU2021205337A1 (en) * | 2020-01-10 | 2022-07-21 | Modernatx, Inc. | Methods of making tolerogenic dendritic cells |
| EP4096720A2 (en) * | 2020-01-30 | 2022-12-07 | ModernaTX, Inc. | Mrnas encoding metabolic reprogramming polypeptides and uses thereof |
| CN118369111A (zh) * | 2021-12-08 | 2024-07-19 | 摩登纳特斯有限公司 | 单纯疱疹病毒mRNA疫苗 |
-
2021
- 2021-06-23 EP EP21748991.3A patent/EP4168556A2/en active Pending
- 2021-06-23 IL IL299196A patent/IL299196A/en unknown
- 2021-06-23 KR KR1020237000782A patent/KR20230042005A/ko not_active Withdrawn
- 2021-06-23 JP JP2022579691A patent/JP2023531511A/ja active Pending
- 2021-06-23 CA CA3187261A patent/CA3187261A1/en active Pending
- 2021-06-23 AU AU2021297248A patent/AU2021297248A1/en not_active Abandoned
- 2021-06-23 US US18/012,094 patent/US20230242908A1/en active Pending
- 2021-06-23 MX MX2022016550A patent/MX2022016550A/es unknown
- 2021-06-23 CN CN202180051902.6A patent/CN116194151A/zh active Pending
- 2021-06-23 WO PCT/US2021/038780 patent/WO2021262909A2/en not_active Ceased
- 2021-06-23 BR BR112022025991A patent/BR112022025991A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20230242908A1 (en) | 2023-08-03 |
| WO2021262909A2 (en) | 2021-12-30 |
| WO2021262909A3 (en) | 2022-04-21 |
| JP2023531511A (ja) | 2023-07-24 |
| AU2021297248A1 (en) | 2023-02-02 |
| CA3187261A1 (en) | 2021-12-30 |
| CN116194151A (zh) | 2023-05-30 |
| IL299196A (en) | 2023-02-01 |
| EP4168556A2 (en) | 2023-04-26 |
| MX2022016550A (es) | 2023-04-10 |
| KR20230042005A (ko) | 2023-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022025991A2 (pt) | Composições de lnp compreendendo terapêutica de mrna com meia-vida prolongada | |
| ECSP23096498A (es) | Restos de administración terapéutica novedosos y usos de estos | |
| CL2021001490A1 (es) | Constructos de iarn modificados químicamente y usos de estos | |
| MX2015013948A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| PE20210114A1 (es) | .COMPOSICIONES DE ARNi CONTRA EL ANGIOTENSINOGENO (AGT) Y METODOS PARA SU USO | |
| CR20170359A (es) | Oligómetros antisentido de tau y usos de estos | |
| BR112023000047A2 (pt) | Compostos de ureia tricíclicos como inibidores da v617f da jak2 | |
| BR112021016833A2 (pt) | Compostos com atividade indutora de ferroptose e métodos de seu uso | |
| BR112019022280A2 (pt) | tratamento de cânceres de her2 positivo | |
| BR112020015915A8 (pt) | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer | |
| BR112018070163A2 (pt) | compostos de aminopurina substituída, composições e métodos de tratamento | |
| BR112017000703A2 (pt) | métodos para tratar ou retardar a progressão do câncer, para reduzir ou inibir a reincidência do câncer, para tratar ou retardar a progressão da imunidade tumoral e para aumentar, intensificar ou estimular uma resposta ou função imune e kit | |
| BR112023001792A2 (pt) | Combinações para o tratamento de câncer | |
| BR112019003731A2 (pt) | aplicação de pridopidina para tratamento de distonias | |
| EA202290001A1 (ru) | Векторы aav с промотором миелинового белка ноль и их применение для лечения заболеваний, связанных со шванновскими клетками, таких как болезнь шарко-мари-тута | |
| BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
| BR112023018944A2 (pt) | Composição de terapia gênica e tratamento de cardiomiopatia arritmogênica ventricular direita | |
| UY39464A (es) | Composiciones y métodos para la prevención y/o tratamiento de la covid-19 | |
| EA202190776A1 (ru) | Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами | |
| CL2024002772A1 (es) | Compuestos de urea triciclicos como inhibidores de jak2 v617f. | |
| CL2023003984A1 (es) | Composiciones del agente de arni de la cinasa de repetición 2 rica en leucina | |
| BR112023003427A2 (pt) | Terapia com antagonista de lag-3 para carcinoma hepatocelular | |
| BR112022008164A2 (pt) | Terapia de combinação para tratar câncer cerebral | |
| MX2021013901A (es) | Composiciones y métodos para el tratamiento del cáncer. | |
| BR112021024997A2 (pt) | Anticorpos, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, métodos e uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |